MA23441A1 - Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88". - Google Patents

Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88".

Info

Publication number
MA23441A1
MA23441A1 MA23768A MA23768A MA23441A1 MA 23441 A1 MA23441 A1 MA 23441A1 MA 23768 A MA23768 A MA 23768A MA 23768 A MA23768 A MA 23768A MA 23441 A1 MA23441 A1 MA 23441A1
Authority
MA
Morocco
Prior art keywords
irp
paroxetine
formulation including
new formulation
amberlite
Prior art date
Application number
MA23768A
Other languages
English (en)
Inventor
Cooper David
Stanley Leonard Graham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA23441A1 publication Critical patent/MA23441A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA23768A 1994-02-03 1995-02-01 Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88". MA23441A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9402029A GB9402029D0 (en) 1994-02-03 1994-02-03 Novel formulation

Publications (1)

Publication Number Publication Date
MA23441A1 true MA23441A1 (fr) 1995-10-01

Family

ID=10749765

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23768A MA23441A1 (fr) 1994-02-03 1995-02-01 Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88".

Country Status (34)

Country Link
US (1) US5811436A (fr)
EP (1) EP0742715B1 (fr)
JP (1) JP4445590B2 (fr)
CN (1) CN1074922C (fr)
AP (2) AP611A (fr)
AT (1) ATE178489T1 (fr)
AU (1) AU682091B2 (fr)
BG (1) BG62843B1 (fr)
BR (1) BR9507055A (fr)
CA (1) CA2182593A1 (fr)
CZ (1) CZ285128B6 (fr)
DE (1) DE69508924T2 (fr)
DK (1) DK0742715T3 (fr)
DZ (1) DZ1850A1 (fr)
ES (1) ES2129806T3 (fr)
FI (1) FI118205B (fr)
GB (1) GB9402029D0 (fr)
GR (1) GR3030131T3 (fr)
HK (1) HK1012288A1 (fr)
HU (1) HUT75941A (fr)
IL (1) IL112521A (fr)
MA (1) MA23441A1 (fr)
MX (1) MX9603203A (fr)
MY (1) MY113036A (fr)
NO (1) NO307954B1 (fr)
NZ (1) NZ278891A (fr)
OA (1) OA10446A (fr)
PL (1) PL178331B1 (fr)
RO (1) RO116342B1 (fr)
RU (1) RU2136281C1 (fr)
SK (1) SK281214B6 (fr)
TW (1) TW436296B (fr)
WO (1) WO1995020964A1 (fr)
ZA (1) ZA95776B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2293247C (fr) * 1997-06-10 2005-04-12 Synthon B.V. Composes 4-phenylpiperidine
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
DE60232290D1 (de) * 2001-04-09 2009-06-25 Rohm & Haas Kontrollierte Auflösung von Wirkstoffen
US20020176842A1 (en) * 2001-04-09 2002-11-28 Lyn Hughes Extended release of active ingredients
US6906206B2 (en) * 2001-04-30 2005-06-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
ATE321530T1 (de) * 2001-08-09 2006-04-15 Smithkline Beecham Plc Zusammensetzung enthaltend paroxetin und ein pharmazeutisch verträgliches salz von glycyrrhizinsäure
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
US6939877B2 (en) * 2002-09-12 2005-09-06 Wyeth Antidepressant piperidine derivatives of heterocycle-fused benzodioxans
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
WO2006023347A1 (fr) * 2004-08-20 2006-03-02 Alpharma, Inc. Formulations à base de paroxétine
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
EP1948646A2 (fr) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees
CN102430122A (zh) * 2005-12-13 2012-05-02 量子高科(北京)研究院有限公司 盐酸氟西汀口腔崩解片及其制备方法
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20100273822A1 (en) * 2009-04-22 2010-10-28 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins
CA2765635C (fr) * 2009-06-25 2016-09-06 Wockhardt Research Centre Composition pharmaceutique de duloxetine ou ses sels pharmaceutiquement acceptables
US8187617B2 (en) * 2009-09-11 2012-05-29 William Wayne Howard Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments
ES2588008T3 (es) 2010-05-19 2016-10-28 Astellas Pharma Inc. Composición farmacéutica que contiene solifenacina
CN104027306A (zh) * 2014-06-25 2014-09-10 万特制药(海南)有限公司 帕罗西汀口服混悬液及其制备方法
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
CN104382870A (zh) * 2014-10-30 2015-03-04 万全万特制药江苏有限公司 一种含有波拉克林钾-帕罗西汀的复合物
CN106309363A (zh) * 2016-09-24 2017-01-11 万特制药(海南)有限公司 盐酸帕罗西汀口服混悬液及其制备方法
CN108926528A (zh) * 2017-05-25 2018-12-04 北京万全德众医药生物技术有限公司 含有氨磺必利树脂酸盐的口服液体组合物
EP3917523A4 (fr) 2019-02-01 2022-10-19 University of South Carolina Compositions de pyridine bicyclique et procédés pour leur utilisation pour la thérapie du cancer
CN113209017B (zh) * 2021-06-02 2023-06-20 上海美优制药有限公司 一种盐酸帕罗西汀混悬剂及其制备方法
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB9005498D0 (en) * 1990-03-12 1990-05-09 Beecham Group Plc Composition
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.

Also Published As

Publication number Publication date
IL112521A (en) 1999-09-22
DK0742715T3 (da) 1999-10-18
DE69508924D1 (de) 1999-05-12
NO963244L (no) 1996-08-02
EP0742715B1 (fr) 1999-04-07
JP4445590B2 (ja) 2010-04-07
DE69508924T2 (de) 1999-10-21
JPH09508402A (ja) 1997-08-26
FI963051A0 (fi) 1996-08-01
CZ285128B6 (cs) 1999-05-12
SK100496A3 (en) 1996-12-04
SK281214B6 (sk) 2001-01-18
AU1536895A (en) 1995-08-21
NO307954B1 (no) 2000-06-26
ZA95776B (en) 1996-08-01
RU2136281C1 (ru) 1999-09-10
RO116342B1 (ro) 2001-01-30
TW436296B (en) 2001-05-28
FI963051A (fi) 1996-08-01
ATE178489T1 (de) 1999-04-15
BG62843B1 (bg) 2000-09-29
PL315679A1 (en) 1996-11-25
PL178331B1 (pl) 2000-04-28
NO963244D0 (no) 1996-08-02
AU682091B2 (en) 1997-09-18
EP0742715A1 (fr) 1996-11-20
CZ229396A3 (en) 1997-01-15
ES2129806T3 (es) 1999-06-16
CN1140411A (zh) 1997-01-15
MX9603203A (es) 1997-03-29
IL112521A0 (en) 1995-05-26
AP9500715A0 (en) 1995-04-30
BG100763A (bg) 1997-03-31
HU9602151D0 (en) 1996-09-30
WO1995020964A1 (fr) 1995-08-10
CA2182593A1 (fr) 1995-08-10
HUT75941A (en) 1997-05-28
OA10446A (en) 2002-03-26
FI118205B (fi) 2007-08-31
AP9600839A0 (en) 1996-07-31
GB9402029D0 (en) 1994-03-30
BR9507055A (pt) 1997-09-02
US5811436A (en) 1998-09-22
AP536A (en) 1996-09-26
HK1012288A1 (en) 1999-07-30
CN1074922C (zh) 2001-11-21
DZ1850A1 (fr) 2002-02-17
GR3030131T3 (en) 1999-07-30
AP611A (en) 1997-09-03
MY113036A (en) 2001-11-30
NZ278891A (en) 1998-01-26

Similar Documents

Publication Publication Date Title
MA23441A1 (fr) Formulation nouvelle comprenant un complexe de paroxetine et d'amberlite "irp 88".
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR9502666A (pt) Eixo articulado
NO308131B1 (no) Hypolipidemiske 1,4-benzotiazepin-1,1-dioksider, anvendelse derav og farmasøytisk blanding
FR2749636B1 (fr) Dispositif d'actionnement
FR2744072B1 (fr) Dispositif d'actionnement
NZ297342A (en) Thiadiazolidin-3-one 1,1-dioxides; medicaments
FI953915A (fi) Dupuytrenin taudin lievittämiseen
ZA958606B (en) A pharmaceutical formulation
FR2687910B1 (fr) Presentoir d'instrumentation dentaire.
FR2769276B1 (fr) Articulation d'accouplement
FR2718999B1 (fr) Dispositif d'attelage auxiliaire.
GB9815170D0 (en) 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7YL)butanoyl-glycyl-3(S)-Quinolin-3- YL-B-alanine and salts thereof
FR2736379B1 (fr) Dispositif d'articulation
FR2753208B1 (fr) Dispositif d'aiguilletage d'un matelas prefixe
FR2730974B1 (fr) Dispositif d'entrainement
FR2744917B1 (fr) Composition therapeutique a base d'acetaminophene
FR2728455B1 (fr) Dispositif d'osteosynthese
ITRM940387A0 (it) "giunto a tampone viscoelastico anidro".
FR2724751B3 (fr) Dispositif d'identification
FR2722099B1 (fr) Nouveau produit de combinaison comprenant de la carpipramine et un neuroleptique.
FR2715291B1 (fr) Dispositif d'ostéosynthèse.
KR970019393U (ko) 브이씨알 헤드의 로타리트랜스포머 연결구조
FR2743177B1 (fr) Dispositif d'affichage
FR2703228B1 (fr) Dispositif d'articulation d'un sommier.